
Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

5 Alarm Bio Ltd raises £500K in seed round
Cambridge Angels, Meltwind, o2h Ventures, SyndicateRoom, as well as other angel investors participated in Five Alarm Bio’s (FAB) seed round with...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...

Iktos SA raises €15.5m in Series A financing
aThe Series A financing of Iktos was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation...

Cydar Medical Ltd raises €10.5m in Series A financing
Besides Pembroke Venture Capital Trust as cornerstone investor with €3.7m (£3m), new investor Downing LLP and existing seed investors supported the...

Noema Pharma AG closes Series B financing
CNS specialist Noema Pharma has cashed in €104m in an oversubscribed Series B fianancing co-led by Jeito Capital and Forbion. New investors such as...